Resolution Bio Liquid Biopsy Outperforms Guardant Test in Lung Cancer Gene Fusion Detection

Resolution Bio Liquid Biopsy Outperforms Guardant Test in Lung Cancer Gene Fusion Detection

NEW YORK (GenomeWeb) – Researchers from the Dana-Farber Cancer Institute and Resolution Biosciences have identified more actionable gene fusion mutations with higher allele frequencies in lung cancer patients using Resolution Bioscience's ctDx-Lung liquid biopsy test than using Guardant Health's Guardant360 assay. GenomeWeb Premium gives you: Never miss another important industry story. You may already have institutional access! Already a GenomeWeb or 360Dx Premium member? *Before your trial expires, we’ll put together a custom quote with your long-term premium options.



Also in Industry News

CDC Coronavirus Testing Decision Likely to Haunt US for Months to Come
CDC Coronavirus Testing Decision Likely to Haunt US for Months to Come

0 Comments

CDC Coronavirus Testing Decision Likely to Haunt US for Months to Come

Read More

Cannabidiol helps fight antibiotic-resistant bacteria
Cannabidiol helps fight antibiotic-resistant bacteria

0 Comments

Cannabidiol helps fight antibiotic-resistant bacteria

Read More

Changes in surface sugarlike molecules help cancer cells to spread
Changes in surface sugarlike molecules help cancer cells to spread

0 Comments

Changes in surface sugarlike molecules help cancer cells to spread

Read More